Literature DB >> 16023810

Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednate.

Masazumi Yamaguchi1, Shin-ichi Yasueda, Akiharu Isowaki, Makiko Yamamoto, Masako Kimura, Katsuhiro Inada, Akira Ohtori.   

Abstract

Preparation of oil-in-water (o/w) type lipid emulsion is one of the approaches to formulate drugs that are poorly water-soluble but can be dissolved in the oil phase of the emulsions. A synthetic glucocorticoid medicine, difluprednate (DFBA), is a water-insoluble compound. We formulated DFBA (0.05%, w/v) ophthalmic lipid emulsion containing 5.0% (w/v) caster oil and 4.0% (w/v) polysorbate 80. The appearance of the emulsion was blue and translucent lipid emulsion, and the median particle size of the lipid emulsion was 104.4 nm. Neither separation nor change in particle size was observed after 6 months at 40 degrees C. Furthermore, when compared with DFBA (0.05%, w/v) ophthalmic suspension, the lipid emulsion showed 5.7-fold higher concentration of DFB that was an active metabolite of DFBA in aqueous humor at 1h after instillation. Ophthalmic lipid emulsion enhances the intraocular penetration of drugs, and it is useful as a delivery system for the ophthalmic preparations of lipophilic drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16023810     DOI: 10.1016/j.ijpharm.2005.05.036

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  10 in total

Review 1.  Review of Approaches for Increasing Ophthalmic Bioavailability for Eye Drop Formulations.

Authors:  Olivia L Lanier; Miranda G Manfre; Claire Bailey; Zhen Liu; Zachary Sparks; Sandesh Kulkarni; Anuj Chauhan
Journal:  AAPS PharmSciTech       Date:  2021-03-14       Impact factor: 3.246

2.  The role of difluprednate ophthalmic emulsion in clinical practice.

Authors:  Karim N Jamal; David G Callanan
Journal:  Clin Ophthalmol       Date:  2009-06-29

3.  Dose uniformity of topical corticosteroid preparations: difluprednate ophthalmic emulsion 0.05% versus branded and generic prednisolone acetate ophthalmic suspension 1%.

Authors:  William Stringer; Roy Bryant
Journal:  Clin Ophthalmol       Date:  2010-10-05

4.  Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride.

Authors:  Hussein O Ammar; H A Salama; M Ghorab; A A Mahmoud
Journal:  AAPS PharmSciTech       Date:  2009-06-18       Impact factor: 3.246

5.  Ophthalmic delivery of brinzolamide by liquid crystalline nanoparticles: in vitro and in vivo evaluation.

Authors:  Weijun Wu; Jing Li; Lin Wu; Baoyan Wang; Zhongyuan Wang; Qunwei Xu; Hongliang Xin
Journal:  AAPS PharmSciTech       Date:  2013-06-29       Impact factor: 3.246

Review 6.  Modern Approaches for Asymmetric Construction of Carbon-Fluorine Quaternary Stereogenic Centers: Synthetic Challenges and Pharmaceutical Needs.

Authors:  Yi Zhu; Jianlin Han; Jiandong Wang; Norio Shibata; Mikiko Sodeoka; Vadim A Soloshonok; Jaime A S Coelho; F Dean Toste
Journal:  Chem Rev       Date:  2018-04-02       Impact factor: 60.622

7.  Topical difluprednate for the treatment of Harada's disease.

Authors:  Spencer M Onishi; Masumi G Asahi; Calvin Chou; Ron P Gallemore
Journal:  Clin Ophthalmol       Date:  2015-01-21

8.  Fatty acid microemulsion for the treatment of neonatal conjunctivitis: quantification, characterisation and evaluation of antimicrobial activity.

Authors:  Ummara Butt; Amr ElShaer; Lori A S Snyder; Athina Chaidemenou; Raid G Alany
Journal:  Drug Deliv Transl Res       Date:  2016-12       Impact factor: 4.617

Review 9.  Ophthalmic drug dosage forms: characterisation and research methods.

Authors:  Przemysław Baranowski; Bożena Karolewicz; Maciej Gajda; Janusz Pluta
Journal:  ScientificWorldJournal       Date:  2014-03-18

Review 10.  Development and Characterization of Nanoemulsions for Ophthalmic Applications: Role of Cationic Surfactants.

Authors:  Ana R Fernandes; Elena Sanchez-Lopez; Tiago Dos Santos; Maria L Garcia; Amelia M Silva; Eliana B Souto
Journal:  Materials (Basel)       Date:  2021-12-08       Impact factor: 3.623

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.